Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivacity-MG: Nipocalimab in Generalized Myasthenia Gravis
NCT03772587Phase 2Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab in myasthenia gravis (MG) (5 arms), sponsored by Momenta Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at Day 113, Treatment-emergent Serious Adverse Events at Day 113 and 2 more. Started Apr 2019; status: completed.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03772587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772587.